World’s First ITVISMA Gene Treatment in Abu Dhabi

World’s First ITVISMA Gene Treatment in Abu Dhabi

Introduction

• Historic Location – Abu Dhabi became the first place in the world where ITVISMA gene therapy was given to a patient with spinal muscular atrophy (SMA).
• Treatment Centre – The treatment was given at Sheikh Khalifa Medical City (SKMC), a major government hospital.
• Regulatory Oversight – The whole process was closely monitored by the Department of Health – Abu Dhabi (DoH).
• Global Milestone – This event is considered a very important step in the field of modern medical treatment.
• Healthcare Leadership – This achievement shows that the UAE is becoming a leader in advanced and modern healthcare.

What Is ITVISMA Gene Therapy?

• Therapy Name – ITVISMA is the medical name of this new gene-based treatment.
• Developer Company – The therapy was developed by the global pharmaceutical company Novartis.
• Target Disease – It is used to treat spinal muscular atrophy (SMA).
• Disease Nature – SMA is a rare genetic disease that slowly weakens muscles and can be life-threatening.
• Gene Replacement – ITVISMA works by replacing the damaged SMN1 gene in the body.
• Protein Production – This helps the body produce an important protein needed for muscle movement.
• Single Dose – The treatment is given only once through an injection into the vein.
• Long-Term Goal – It is meant to give long-lasting improvement without repeated hospital visits.

Regulatory Approvals and Global Context

• UAE Approval – The Emirates Drug Establishment (EDE) officially approved ITVISMA on 25 November 2025.
• Clinical Review – Before approval, doctors studied patient results to ensure safety and effectiveness.
• Global Standing – With this approval, the UAE joined the very few countries allowing this treatment.
• US Approval – The United States Food and Drug Administration (FDA) has also approved this therapy.
• Expanded Eligibility – It can be used for patients aged two years and above with confirmed SMA.
• Medical Advancement – This approval made advanced treatment available to more patients worldwide.

The Historic First Administration

• Administration Date – The world’s first dose of ITVISMA was given on 28 December 2025.
• Hospital Role – Sheikh Khalifa Medical City carried out the treatment successfully.
• Official Supervision – Health authorities in Abu Dhabi closely supervised the entire process.
• Patient Privacy – Details about the patient were kept private for safety and dignity.
• Age Expansion – The therapy can now be given to both children and adults.
• Treatment Scope – Earlier treatments were mostly for babies, but this one is for older patients too.
• Clinical Breakthrough – This marked a big improvement in how SMA is treated.

Significance of This Milestone

Global Healthcare Leadership

• Medical Hub – Abu Dhabi is now seen as an important centre for advanced medical treatment.
• Innovation Focus – The city focuses strongly on new and modern healthcare solutions.
• Rare Disease Care – Special attention is being given to rare and serious genetic diseases.

Patient Impact

• New Hope – SMA patients now have new hope for a better life.
• Root Cause – The treatment works on the real cause of the disease, not just symptoms.
• Motor Improvement – Patients may gain better muscle movement and strength.
• Quality Life – This can help patients live longer and more independent lives.

Ecosystem Strength

• Integrated System – Hospitals, government bodies, and health partners worked together smoothly.
• Key Institutions – DoH, SKMC, PureHealth, and international companies played important roles.
• Regulatory Speed – Quick approvals helped patients get treatment on time.
• Global Partnerships – Working with global medicine companies made this success possible.

Expert Perspectives

• DoH Statement – Health officials said this proves Abu Dhabi’s strong healthcare system.
• Precision Commitment – The government is committed to modern, gene-based treatments.
• Hospital View – Hospital leaders called it a proud moment for the medical team.
• Industry Insight – Novartis officials praised teamwork between the UAE and global partners.
• Access Acceleration – Experts said patients now get faster access to advanced medicines.

Future Implications

• Regional Adoption – Other Middle East countries may follow Abu Dhabi’s example.
• Gene Therapy Growth – More gene-based treatments may be introduced in the future.
• Medical Innovation – This success encourages further medical research and development.
• Patient Outcomes – Future treatments may help even more patients live healthier lives.
• Research Momentum – Confidence in genetic medicine is increasing worldwide.

Important Questions

1. What is ITVISMA gene therapy and which disease is it used to treat?
2. Why is Abu Dhabi’s administration of ITVISMA considered a historic medical milestone?
3. How does ITVISMA gene therapy work to improve the condition of SMA patients?
4. Which institutions and authorities were involved in the first administration of ITVISMA in Abu Dhabi?
5. What impact can the success of ITVISMA have on the future of gene therapy and rare disease treatment?

Conclusion

The first administration of ITVISMA gene therapy in Abu Dhabi is a historic step in modern healthcare, showing how advanced medical science can directly improve lives. It highlights the UAE’s strong healthcare system, quick regulatory support, and focus on treating rare genetic diseases at their root. This achievement not only brings new hope to SMA patients but also opens the door for wider use of gene therapies in the future, both in the region and around the world.